Skip to main content
SpringerLink
Log in

GLP-1: soltanto la glicemia?

  • Rassegna
  • Published:
L'Endocrinologo Aims and scope

Sommario

Gli analoghi del GLP-1 (GLP-1Ras) rappresentano una valida opzione terapeutica per il trattamento dei pazienti con diabete mellito tipo 2, soprattutto per i vantaggi in termini di efficacia sul controllo glicemico e ridotto rischio di ipoglicemia. Dalla loro introduzione in commercio, vi è stato un crescente interesse verso i GLP-1RAs in ragione anche dei numerosi effetti extraglicemici, che vanno dalla riduzione del peso corporeo, della pressione arteriosa, dei livelli circolanti di lipidi e di marcatori dell’infiammazione, fino a specifici effetti cardiovascolari e renali. In particolare, gli studi di sicurezza cardiovascolare, condotti con alcune delle molecole di questa classe, hanno dimostrato la riduzione del rischio di eventi cardiovascolari maggiori e di nefropatia, i cui meccanismi sottostanti sono attualmente oggetto di estesa ricerca.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Bibliografia

  1. Rizzo M, Nikolic D, Patti AM et al. (2018) GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms. Biochim Biophys Acta Mol Basis Dis 1864:2814–2821

    Article  CAS  PubMed  Google Scholar 

  2. Nauck MA, Meier JJ, Cavender MA et al. (2017) Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation 136:849–870

    Article  CAS  PubMed  Google Scholar 

  3. Luconi M, Cantini G, Ceriello A et al. (2017) Perspectives on cardiovascular effects of incretin-based drugs: from bedside to bench, return trip. Int J Cardiol 241:302–310

    Article  PubMed  Google Scholar 

  4. Meier JJ (2012) GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 8:728–742

    Article  CAS  PubMed  Google Scholar 

  5. Rizzo M, Rizvi AA, Patti AM et al. (2016) Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study. Cardiovasc Diabetol 15:162

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Mazidi M, Karimi E, Rezaie P et al. (2017) Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. J Diabetes Complicat 31:1237–1242

    Article  Google Scholar 

  7. Russo GT, Labate AM, Giandalia A et al. (2015) Twelve-month treatment with liraglutide ameliorates visceral adiposity index and common cardiovascular risk factors in type 2 diabetes outpatients. J Endocrinol Invest 38:81–89

    Article  CAS  PubMed  Google Scholar 

  8. Simioni N, Berra C, Boemi M et al. for the ReaL (NN2211-4118) Study Group (2018) Predictors of treatment response to liraglutide in type 2 diabetes in a real-world setting. Acta Diabetol 55:557–568

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Pfeffer MA, Claggett B, Diaz R et al. for the ELIXA Investigators (2015) Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373:2247–2257

    Article  CAS  PubMed  Google Scholar 

  10. Marso SP, Daniels GH, Brown-Frandsen K, et al. for the LEADER Trial Investigators (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:311–322

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Marso SP, Bain SC, Consoli A et al. for the SUSTAIN-6 Investigators (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes N Engl J Med 375:1834–1844

    Article  CAS  PubMed  Google Scholar 

  12. Holman RR, Bethel MA, Mentz RJ et al. for the EXSCEL Study Group (2017) Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 377:1228–1239

    Article  CAS  PubMed  Google Scholar 

  13. Hernandez AF, Green JB, Janmohamed S et al. for the Harmony Outcomes committees and investigators (2018) Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392(10157):1519–1529

    Article  CAS  PubMed  Google Scholar 

  14. Gerstein HC, Colhoun HM, Dagenais GR, et al. for the REWIND Trial Investigators (2017) Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. Diabetes Obes Metab 20(1):42–49

    Article  CAS  PubMed  Google Scholar 

  15. Bethel MA, Patel RA, Merrill P et al. for the EXSCEL Study Group (2018) Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol 6:105–113

    Article  PubMed  Google Scholar 

  16. Song X, Jia H, Jiang Y et al. (2015) Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 diabetes mellitus: a meta-analysis. Sci Rep 5:10202

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Mann JF, Orsted DD, Orsted DD et al. for the LEADER Steering Committee and Investigators (2017) Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 377:839–848

    Article  CAS  PubMed  Google Scholar 

  18. Dicembrini I, Nreu B, Scatena A et al. (2017) Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials. Acta Diabetol 54:933–941

    Article  CAS  PubMed  Google Scholar 

  19. Tuttle KR, Lakshmanan MC, Rayner B et al. (2018) Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol 6:605–617

    Article  CAS  PubMed  Google Scholar 

  20. Associazione Medici Diabetologi (AMD) e Società Italiana di Diabetologia (SID) (2018) Standard italiani per la cura del diabete mellito 2018. aemmedi.it/amd-sid-standard-di-cura-del-diabete-mellito-2018/. Accessed

Download references

Author information

Authors and Affiliations

  1. Dipartimento di Medicina Clinica e Sperimentale, Università degli Studi di Messina, Messina, Italia

    Giuseppina T. Russo, Annalisa Giandalia & Domenico Cucinotta

Authors
  1. Giuseppina T. Russo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Annalisa Giandalia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Domenico Cucinotta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Domenico Cucinotta.

Ethics declarations

Conflitto di interesse

Gli autori Giuseppina T. Russo, Annalisa Giandalia e Domenico Cucinotta dichiarano di non avere conflitti di interesse.

Consenso informato

Lo studio presentato in questo articolo non ha richiesto sperimentazione umana.

Studi sugli animali

Gli autori di questo articolo non hanno eseguito studi sugli animali.

Additional information

Proposto da Francesco Trimarchi.

Materiale elettronico supplementare

I link al materiale elettronico supplementare sono elencati qui sotto.

(DOCX 18 kB)

(DOCX 17 kB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Russo, G.T., Giandalia, A. & Cucinotta, D. GLP-1: soltanto la glicemia?. L'Endocrinologo 20, 66–71 (2019). https://doi.org/10.1007/s40619-019-00537-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40619-019-00537-w

Parole chiave

Search

Navigation